Results 201 to 210 of about 180,190 (229)

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Treat and extend protocol outcomes in diabetic macular edema: A narrative review

American Journal of Ophthalmic Clinical Trials, 2022
The objective of this study was to pool available data on change in visual acuity, number of injections, and change in central subfield thickness as reported by treat and extend (T&E) regimens for diabetic macular edema (DME) compared to monthly and pro re nata (PRN) regimens.
Param Bhatter, Abhinav Bheemidi, Justin C. Muste, Shirley Z. Wu, Molly J. E. Snider, Carolina C. S. Valentim, Rishi P. Singh   +6 more
openaire   +1 more source

TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION

Retina, 2016
To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve retinal angiomatous proliferation (RAP) and development of retinal pigment epithelium (RPE) atrophy.We retrospectively studied 17 treated eyes with RAP and 13 untreated fellow eyes.
Hidetaka, Matsumoto, Taku, Sato, Masahiro, Morimoto, Ryo, Mukai, Maki, Takahashi, Takashi, Hiroe, Kensuke, Ehara, Mayuko, Takayama, Kensuke, Mimura, Shoji, Kishi   +9 more
openaire   +2 more sources

Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy

British Journal of Ophthalmology, 2018
AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the
Ahmad M, Mansour, Abdulrazzak, Charbaji, Michel Eid, Farah, Hana A, Mansour, Jay, Chhablani   +4 more
openaire   +2 more sources

Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial

Japanese Journal of Ophthalmology, 2021
To investigate the efficacy and safety of a treat-and-extend (T&E) regimen using aflibercept (Eylea) for diabetic macular edema (DME).Prospective, open-label, multicenter, single-arm, nonblinded clinical study.Forty eyes of 40 patients with DME received a T&E regimen of intravitreal aflibercept injection (IAI) with the longest treatment interval set to
Takao, Hirano, Yuichi, Toriyama, Yoshihiro, Takamura, Masahiko, Sugimoto, Taiji, Nagaoka, Yoshimi, Sugiura, Fumiki, Okamoto, Michiyuki, Saito, Kousuke, Noda, Shigeo, Yoshida, Akihiro, Ishibazawa, Osamu, Sawada, Toshinori, Murata   +12 more
openaire   +2 more sources

TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY

Retina, 2017
To investigate the efficacy of a treat-and-extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV).We retrospectively reviewed the medical records of 29 patients with PCV, who had been treated with a TER for 1 year. The primary outcome was the proportion of eyes that did not lose ≥3 best-corrected visual acuity (BCVA ...
Kang Yeun, Pak, Sung Who, Park, Ik Soo, Byon, Ji Eun, Lee   +3 more
openaire   +2 more sources

Treat and extend regimen for diabetic macular oedema—a systematic review and meta-analysis

Graefe's Archive for Clinical and Experimental Ophthalmology, 2022
Various treatment regimens are currently practiced in the treatment of CI-DMO (centre-involving diabetic macular oedema). In recent years, there has been a growing body of evidence supporting a treat and extend (T&E) regimen for DMO which offers the promise of comparable visual and anatomical outcomes while reducing injection burden. This meta-analysis
Sheng Yang Lim, Wendy Meihua Wong, Ivan Seah, Hwei Wuen Chan, Xinyi Su, Gopal Lingam, Yew Sen Yuen   +6 more
openaire   +2 more sources

Treat and extend versus PRN in diabetic retinopathy

Acta Ophthalmologica, 2016
SummaryVascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of the neo‐vascular age related macular degeneration (nAMD) and the ischemic retinal microangiopathies. Targeting VEGF in retinal diseases became an effective therapeutic option.To optimize the benefit of risk ratio and cost effectiveness of anti‐VEGF agents, a number
openaire   +1 more source